Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W B Harris

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal (National Association for Hospital Development (U.S.))|January 7, 1977
Starting from scratchW B Harris
Seminars in Oncology|May 5, 1998
Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancerK Bhalla, W B Harris
The Journal of Surgical Research|June 1, 1985
Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutritionW B Harris, V B Grossie, D M Ota, et al.
The Journal of Urology|August 19, 2011
Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinomaT V Johnson, S Ali, A Abbasi, et al.
Urology|April 17, 2010
Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinomaT V Johnson, A Abbasi, A Owen-Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignanciesD Mahadevan, E G Chiorean, W B Harris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinomaM H Voss, A Hussain, N Vogelzang, et al.
Bone Marrow Transplantation|July 19, 2016
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumorsZ DeFilipp, C B Rosand, D A Goldstein, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal (National Association for Hospital Development (U.S.))|January 7, 1977
Starting from scratchW B Harris
Seminars in Oncology|May 5, 1998
Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancerK Bhalla, W B Harris
The Journal of Surgical Research|June 1, 1985
Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutritionW B Harris, V B Grossie, D M Ota, et al.
The Journal of Urology|August 19, 2011
Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinomaT V Johnson, S Ali, A Abbasi, et al.
Urology|April 17, 2010
Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinomaT V Johnson, A Abbasi, A Owen-Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignanciesD Mahadevan, E G Chiorean, W B Harris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinomaM H Voss, A Hussain, N Vogelzang, et al.
Bone Marrow Transplantation|July 19, 2016
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumorsZ DeFilipp, C B Rosand, D A Goldstein, et al.
Pageof 1